Combination of Neostigmine and Metoclopramide to reduce gastric residual volume in mechanically ventilated ICU patients
Phase 2
- Conditions
- The relation of combination of Neostigmine and Metoclopramide with gastric residual volume in mechanically ventilated ICU patients.
- Registration Number
- IRCT201408104365N16
- Lead Sponsor
- Vice chancellor for research of Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
patient family agreement and informed written consent; under mechanical ventilation; nutrition via gastric tube; gastric residual volume greater than 120 cc; age between 20 and 60 years
Exclusion criteria: diabetes; heart rate<60; heart blocks and arrhythmias; systolic BP<90 mmHg; hypothermia (core temperature<35); renal failure (serum Creatinin>1.5 in two consecutive test); prokinetic agents consumption during 8 hours before intervention; recent surgery on GI tract within 10 days; pregnancy and breast feeding; extrapyramidal sign; bronchospasm; hypokalemia (K<3 meq/L); known sensitivity to Neostigmine and metoclopramide; GI bleeding.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gastric residual volume. Timepoint: 0,3,6,9,12 hours after intervention. Method of measurement: Gastric lavage.
- Secondary Outcome Measures
Name Time Method Albumin, hemoglobin, WBC, Na, K, Mg. Timepoint: Before trial. Method of measurement: laboratory kit.;Hear rate, blood pressure. Timepoint: During trial. Method of measurement: Cardiac monitoring.;SOFA. Timepoint: before trial. Method of measurement: SOFA calculator.